Oppenheimer lowered the firm’s price target on Cellectis to $10 from $11 and keeps an Outperform rating on the shares after the company provided business updates and reported financial results for Q1. The firm spoke with management recently, with the company continuing to be confident with its in-house manufactured UCART22 P2, if an accelerated approval pathway materializes. Meanwhile, Oppenheimer awaits UCART22 and UCART20x22 programs to complete escalation phase by year-end 2024.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLLS:
- Monthly information on share capital and company voting rights
- Cellectis Gains Orphan Drug Status for Leukemia Therapy
- Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
- Cellectis aanounces EG granted ODD to product candidate UCART22
- Cellectis SA Announces Upcoming Annual Meeting